StreetInsider.com News Articles

Form PRE 14A Lifeward Ltd. For: Sep 15

Tue, 15 Sep 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260915/27065907.html

Form 8-K Lifeward Ltd. For: Sep 15

Tue, 15 Sep 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260915/27065814.html

Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

Tue, 15 Sep 2026 08:00:00 -0400

Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use

ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton

Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized

Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

Tue, 15 Sep 2026 08:00:00 -0400

Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use

ReWalk users with chronic spinal cord injury were able to perform everyday kitchen and grooming activities while standing with a personal exoskeleton

Publication adds to clinical evidence supporting ReWalk as sales and national distribution access continue to expand

Form 4 Lifeward Ltd. For: Aug 14 Filed by: Zamir Haggai

Thu, 10 Sep 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260910/27046266.html

Form 3 Lifeward Ltd. For: Aug 14 Filed by: Zamir Haggai

Thu, 10 Sep 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20260910/27046237.html

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Tue, 08 Sep 2026 08:30:00 -0400

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an updated investor presentation is available on the Company's investor relations website.

The presentation provides an overview of Lifeward's strategy to scale its established rehabilitation platform, leverage its reimbursement infrastructure, and expand its capital-efficient distribution network. It also highlights the Company's recent commercial performance, product development pipeline and strategic partnership with Oramed Pharmaceuticals

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

Tue, 08 Sep 2026 08:30:00 -0400

Lifeward names interim CEO and CFO amid leadership change

Mon, 31 Aug 2026 16:15:21 -0400

Lifeward Ltd. (Nasdaq: LFWD) announced the appointment of Josh Hexter as Interim Chief Executive Officer, effective September 1, 2026, and Rami Aviram as Chief Financial Officer, effective November 1, 2026, according to a company statement.

Hexter succeeds Mark Grant, who is leaving Lifeward to pursue other opportunities. Grant will remain as a consultant through September 30, 2026 to assist with the transition. Hexter brings nearly three decades of life sciences experience, including roles as Chief Operating and Business Officer of Oramed Pharmaceuticals, Chief Business Officer of BrainsWay, and Executive Director of Corporate In-Licensing at BioLineRx. He also founded Biosensor Systems Design,

Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer

Mon, 31 Aug 2026 16:15:00 -0400

Experienced leadership team to build on established commercial platform and accelerate Lifeward’s next phase of growth with continuity of strategy

HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of Josh Hexter as Interim Chief Executive Officer effective September 1, 2026 and Rami Aviram as Chief Financial Officer effective November 1, 2026.

Hexter succeeds Mark Grant, who has chosen to leave Lifeward to

Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer

Mon, 31 Aug 2026 16:15:00 -0400

Experienced leadership team to build on established commercial platform and accelerate Lifeward’s next phase of growth with continuity of strategy

Hexter succeeds Mark Grant, who has chosen to leave Lifeward to

Form 4 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260828/26998250.html

Form 4 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260828/26998250.html

Form 3 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998102.html

Form 3 Lifeward Ltd. For: Aug 14 Filed by: Greenwald Yonason

Fri, 28 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260828/26998102.html

Form 4 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260824/26969054.html

Form 4 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260824/26969054.html

Form 3 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260824/26969037.html

Form 3 Lifeward Ltd. For: Aug 20 Filed by: Gabay Avraham

Mon, 24 Aug 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260824/26969037.html

H.C. Wainwright Reiterates Buy Rating on Lifeward (LFWD)

Fri, 21 Aug 2026 07:04:04 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $10.00 price target on Lifeward (NASDAQ: LFWD).

The analyst commented: "Last week, Lifeward reported 2Q26 financial results. 2Q26 total revenues of $6.6M grew 16% YoY from $5.7M in 2Q25, and represent the strongest quarterly revenue performance since 4Q24, with US-based revenue grew 33% YoY to $4.1M. ReWalk Personal Exoskeleton sales rose 13% YoY to $2.5M, driven primarily by stronger demand in Europe and higher CMS revenue, while AlterG products and services grew 25% YoY to $4.1M on higher US unit shipments, service revenue, and average selling prices. Management expects revenue momentum

Form 8-K Lifeward Ltd. For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956167.html

Form 8-K Lifeward Ltd. For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956167.html

Nano Dimension names Nadav Kidron to board, to chair new committee

Mon, 17 Aug 2026 08:01:58 -0400

Nano Dimension Ltd. (NASDAQ: NNDM) has appointed Nadav Kidron to its board of directors, where he will chair a newly formed Strategy and Capital Allocation Committee, according to a company statement.

The committee, part of an ongoing strategic review led by board Chairman Phillip Borenstein, will evaluate capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets, and other strategic opportunities.

Kidron is the president and chief executive officer of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), which is described as a significant shareholder of Nano Dimension. He also serves on the boards of Alpha Tau Medical Ltd. (NASDAQ: DRTS)

Nano Dimension names Nadav Kidron to board, to chair new committee

Mon, 17 Aug 2026 08:01:58 -0400

Nano Dimension names Nadav Kidron to board, to chair new committee

Mon, 17 Aug 2026 08:01:58 -0400